论文部分内容阅读
目的探讨<8月婴幼儿接种麻疹类疫苗其血清IgG保护性,以评价起始月龄<8月龄接种麻疹类疫苗可行性与必要性。方法对2011年采集麻疹血清学调查中发现的10例第1剂次提前接种的儿童与在8~12月龄接种第1剂次的儿童对照,分别以年龄、性别、接种剂次、2剂次之间时间间隔(年)、最后1剂次距监测时间间隔(年)等条件按照1∶4进行配对,采用酶联免疫吸附试验(ELISA)间接法检测麻疹IgG抗体,应用EPI-INFO统计分析软件,比较后期抗体麻疹IgG抗体显性感染保护水平之间的差别。结果麻疹类疫苗首剂接种起始月龄<8月龄将明显降低远期疫苗的显性感染保护水平,而提前接种麻疹疫苗并不能降低<8月龄儿童的麻疹发病率(χ2=12.22,P<0.01,α=0.05,ORMLE=0.07,ORMLE95%CI为(0.01,0.83))。结论不建议将麻疹首剂接种时间提前至8月龄前。
Objective To investigate the serum IgG protective effect of measles vaccine in infants and young children in August to evaluate the feasibility and necessity of measles vaccine inoculated at <8 months old. Methods A total of 10 children inoculated with the first dose of measles collected from the 2011 serological survey of measles were compared with the children in the first dose of the vaccine administered from 8 to 12 months of age. The age, sex, inoculation, The time interval (years), the last dose from the monitoring time interval (years) and other conditions according to 1: 4 paired, the enzyme-linked immunosorbent assay (ELISA) indirect detection of measles IgG antibodies, the application of EPI-INFO statistics Analysis software to compare the differences between late-stage measles IgG antibody dominant infection protection levels. Results The first month of vaccination of measles vaccine at the age of <8 months significantly reduced the level of dominant infection protection of the long-term vaccine. However, measles vaccine vaccination did not reduce the incidence of measles in children <8 months (χ2 = 12.22, P <0.01, α = 0.05, ORMLE = 0.07, ORMLE 95% CI was (0.01, 0.83)). Conclusion It is not advisable to pre-vaccinate the first dose of measles to be before 8 months of age.